Gastric cancer displays marked molecular heterogeneity with aggressive behavior and treatment resistance. Therefore, good in vitro models that encompass unique subtypes are urgently needed for precision medicine development. Here, we have established a primary gastric cancer organoid (GCO) biobank that comprises normal, dysplastic, cancer and lymph node metastases (n=63) from 34 patients, including detailed whole-exome and transcriptome analysis. The cohort encompasses most known molecular subtypes (including EBV, MSI, intestinal/CIN, and diffuse/GS, with CLDN18-ARHGAP6 or CTNND1-ARHGAP26 fusions or RHOA mutations), capturing regional heterogeneity and subclonal architecture, while their morphology, transcriptome, and genomic profiles remain closely similar to in vivo tumors, even after long-term culture. Large-scale drug screening revealed sensitivity to unexpected drugs that were recently approved or in clinical trials, including Napabucasin, Abemaciclib, and the ATR inhibitor VE-822. Overall, this new GCO biobank, with linked genomic data, provides a useful resource for studying both cancer cell biology and precision cancer therapy.
Differentiation of mesoderm pericytes from induced pluripotent stem cell lines.
Short-read transcriptomic data of unaffected control, expansion negative, and expansion positive FECD CECs
Longitudinal analysis of single-cell RNAseq datasets of PBMCs from COVID-19 CVID patients and controls.
Spatial transcriptomics of human Mycobacterium granulomas reveals Spatial and Functional Architecture of Immune Response and Tissue Remodeling
Single-cell G&T seq from an untreated PDX mouse with neuroblastoma (MYCN amplified).